Role of lipid metabolism in CD8+ T cell ferroptosis
Role of lipid metabolism in CD8+ T cell ferroptosis
批准号:
10792062
负责人:
Qing Yi
金额:
$48.45万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-09-19 至 2028-08-31
关键词:
Adoptive Cell TransfersBedsBloodBone MarrowCD36 geneCD8-Positive T-LymphocytesCD8B1 geneCancer PatientCell physiologyCellsCellular Metabolic ProcessCessation of lifeClinicalCoenzyme ACytotoxic T-LymphocytesDataEnzymesFatty AcidsFunctional disorderGene ExpressionGenesImmunotherapyImpairmentIn complete remissionIndividualInfiltrationInterferon Type IILipid PeroxidationMalignant NeoplasmsMediatingMelanoma CellMemoryMetabolicMethodsModelingMultiple MyelomaMusOxidoreductasePatientsPolyunsaturated Fatty AcidsProductionPrognosisPublicationsReportingRoleT-LymphocyteTNF geneTestingTreatment EfficacyTumor Burdencancer immunotherapycancer infiltrating T cellscomparison controlcytokinecytotoxiccytotoxic CD8 T cellseffector T cellfatty acid oxidationimmune checkpoint blockadeimprovedindividual patientknock-downlipid metabolismmelanomanew therapeutic targetnovelnovel therapeutic interventionoxidationprogramsresponsesingle-cell RNA sequencingsuccesstranscriptome sequencingtumortumor microenvironmentuptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Recently, we made a novel and exciting discovery that tumors or the tumor microenvironment (TME) cause T-
cell dysfunction and death by inducing ferroptosis in T cells. We analyzed the sc-RNA-seq data of tumor-
infiltrating T cells from melanoma patients and discovered that tumor-infiltrating CD8+ T cells had significantly
increased expressions of genes associated with lipid peroxidation and ferroptosis compared to blood CD8+ T
cells from healthy individuals. More importantly, our unpublished studies further revealed that among different
CD8+ T cell subpopulations, effector memory (TEM) and terminally differentiated effector (TTE) CD8+ T cells are
more sensitive to tumor-induced ferroptosis. We examined tumor-infiltrating CD8+ T cells from the bone
marrow (BM; tumor bed) of patients with multiple myeloma. By separating the T cells into naïve, TTE or TEM
cells based on their expression of CCR7 and CD45RA, we found that TEM and TTE CD8+ T cells expressed
higher levels of lipid peroxidation- and ferroptosis-associated genes and were more sensitive to tumor-induced
ferroptosis compared to naïve CD8+ T cells although they expressed similar levels of CD36. Similarly, in
mouse melanoma and MM models, increased ferroptosis mainly occurred in tumor-infiltrating CD8+ TEM and
TTE cells but not in naïve CD8+ T cells from mice with large tumor burdens compared to those with small tumor
burdens. Our ex vivo studies confirmed that CD8+ TEM and TTE cells were more sensitive to tumor- or FA-
induced ferroptosis than naïve T cells and their production of cytotoxic cytokines such as IFNγ and TNFα was
inhibited. To elucidate the underlying mechanisms, RNA-seq was used and showed that CD8+ TEM and TTE
cells expressed a significantly lower level of 2,4-dienoyl-CoA reductase 1 (DECR1), a rate-limiting enzyme for
polyunsaturated fatty acid (PUFA) β-oxidation, compared to naïve CD8+ T cells. Knockdown (KD) of DECR1 in
naïve CD8+ T cells resulted in an increased PUFA expression and peroxisomal dysfunction and sensitized
them to tumor- or FA-induced ferroptosis than control T cells. Based on these novel findings, we hypothesize
that CD8+ TEM and TTE cells, due to uptake of more FAs and reduced expression of DECR1 and PUFA
oxidation, are sensitive to tumor/TME-induced ferroptosis, and inhibiting TEM and TTE cell ferroptosis may
effectively enhance the therapeutic efficacy of immunotherapy in cancer patients. Aim 1 will determine the
mechanism underlying tumor- or FA-induced ferroptosis in CD8+ TEM and TTE cells in TME. Aim 2 will elucidate
the role and mechanisms of tumor and TME accumulation of FAs and induction of lipid peroxidation in CD8+
TEM and TTE T cells and Aim 3 will inhibit CD8+ TEM and TTE cell ferroptosis to enhance the efficacy of cancer
immunotherapies. Accomplishing these aims will provide us with in-depth understanding of the mechanisms
underlying how tumors and the TME induce T cell lipid peroxidation and how ferroptosis mediates T cell
metabolic malfunction and death. Understanding these mechanisms is extremely important and will greatly
assist us in developing novel therapeutic approaches to target T cell lipid metabolism and TME to significantly
improve the efficacy of cancer immunotherapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel mechanism of induction of tumor pyroptosis by IL-9-secreting Tc9 cells
-
批准号:10704861
-
项目类别:
-
资助金额:$47.32万
-
财政年份:2023
-
负责人:Qing Yi
-
依托单位:
Role of tumor microenvironment-derived cholesterol in CD8+ T-cell exhaustion
-
批准号:10673683
-
项目类别:
-
资助金额:$41.7万
-
财政年份:2019
-
负责人:Qing Yi
-
依托单位:
Role of tumor microenvironment-derived cholesterol in CD8+ T-cell exhaustion
-
批准号:10251255
-
项目类别:
-
资助金额:$42.55万
-
财政年份:2019
-
负责人:Qing Yi
-
依托单位:
Role of tumor microenvironment-derived cholesterol in CD8+ T-cell exhaustion
-
批准号:10456222
-
项目类别:
-
资助金额:$41.7万
-
财政年份:2019
-
负责人:Qing Yi
-
依托单位:
Role of MIF in myeloma bone homing and drug response
-
批准号:9211149
-
项目类别:
-
资助金额:$36.26万
-
财政年份:2017
-
负责人:Qing Yi
-
依托单位:
Targeting macrophages to sensitize myeloma to immune checkpoint blockade
-
批准号:9634041
-
项目类别:
-
资助金额:$33.51万
-
财政年份:2017
-
负责人:Qing Yi
-
依托单位:
Targeting macrophages to sensitize myeloma to immune checkpoint blockade
-
批准号:10091406
-
项目类别:
-
资助金额:$33.51万
-
财政年份:2017
-
负责人:Qing Yi
-
依托单位:
Role of MIF in myeloma bone homing and drug response
-
批准号:10078263
-
项目类别:
-
资助金额:$36.94万
-
财政年份:2017
-
负责人:Qing Yi
-
依托单位:
Targeting macrophages to sensitize myeloma to immune checkpoint blockade
-
批准号:9283894
-
项目类别:
-
资助金额:$32.89万
-
财政年份:2017
-
负责人:Qing Yi
-
依托单位:
A novel T-cell subset able to kill relapsed cancers
-
批准号:9291443
-
项目类别:
-
资助金额:$36.26万
-
财政年份:2016
-
负责人:Qing Yi
-
依托单位:
A novel T-cell subset able to kill relapsed cancers
-
批准号:10006728
-
项目类别:
-
资助金额:$36.94万
-
财政年份:2016
-
负责人:Qing Yi
-
依托单位:
Targeting Plasmacytoid Dendritic Cells to Treat Human Myeloma
-
批准号:8609556
-
项目类别:
-
资助金额:$38.33万
-
财政年份:2012
-
负责人:Qing Yi
-
依托单位:
C-reactive protein promotes myeloma cell-mediated bone destruction
-
批准号:8715069
-
项目类别:
-
资助金额:$24.22万
-
财政年份:2010
-
负责人:Qing Yi
-
依托单位:
C-reactive protein promotes myeloma cell-mediated bone destruction
-
批准号:8209290
-
项目类别:
-
资助金额:$35.78万
-
财政年份:2010
-
负责人:Qing Yi
-
依托单位:
C-reactive protein promotes myeloma cell-mediated bone destruction
-
批准号:8403708
-
项目类别:
-
资助金额:$9.13万
-
财政年份:2010
-
负责人:Qing Yi
-
依托单位:
Animals Models Core
-
批准号:7976008
-
项目类别:
-
资助金额:$6.41万
-
财政年份:2010
-
负责人:Qing Yi
-
依托单位:
P2 - ANTI-B2-MICR0GL0BULIN ANTIBODIES AS THERAPEUTIC AGENTS FOR MULTIPLE MYELOMA
-
批准号:7975983
-
项目类别:
-
资助金额:$18.17万
-
财政年份:2010
-
负责人:Qing Yi
-
依托单位:
C-reactive protein promotes myeloma cell-mediated bone destruction
-
批准号:8091352
-
项目类别:
-
资助金额:$35.78万
-
财政年份:2010
-
负责人:Qing Yi
-
依托单位:
C-reactive protein promotes myeloma cell-mediated bone destruction
-
批准号:8595291
-
项目类别:
-
资助金额:$34.81万
-
财政年份:2010
-
负责人:Qing Yi
-
依托单位:
C-reactive protein promotes myeloma cell-mediated bone destruction
-
批准号:7982993
-
项目类别:
-
资助金额:$16.39万
-
财政年份:2010
-
负责人:Qing Yi
-
依托单位:
海外基金